Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Share-based Compensation for 10 years, with the latest figure at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 29.79% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $39.3 million (up 25.86% YoY), and the FY2025 full-year result was $37.0 million, up 20.56% from the prior year.
• Share-based Compensation for Q1 2026 stood at $10.1 million, down from $10.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $10.2 million in Q4 2025, with the low at $6.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $7.6 million across 5 years, with a median of $7.4 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation retreated 15.37% — and 2026, when it gained 29.79%.
• Kiniksa Pharmaceuticals International's Share-based Compensation stood at $6.4 million in 2022, then advanced by 21.99% to $7.8 million in 2023, then rose by 6.75% to $8.3 million in 2024, then advanced by 23.34% to $10.2 million in 2025, then slipped by 1.75% to $10.1 million in 2026.
• The last three Share-based Compensation figures came in at $10.1 million (Q1 2026), $10.2 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.